Gland Pharma Stock Jumps on Global Injectables Supply Deal

Gland Pharma shares advanced by 2.48% today, trading at Rs. 2665.00, following the execution of a significant Manufacturing and Supply Agreement with a leading global pharmaceutical company.

The strategic pact focuses on the technology transfer, manufacturing, and long-term supply of a portfolio of sterile injectable products destined for global markets, signaling strong business visibility for Gland Pharma.

Strategic Global Partnership

The agreement positions Gland Pharma as an integrated end-to-end partner, supporting multiple products through various lifecycle stages, including both commercially marketed items and pipeline developments.

• This collaboration operates under a full-service CDMO model.
• It encompasses technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.

Diversified Product Portfolio

The portfolio under the agreement includes a varied selection of oncology and non-oncology products, addressing both complex and conventional injectable formulations.

• Products will be presented in Vial, Lyo, Ampoules, and pre-filled syringe (PFS) formats.
• Gland Pharma will leverage its integrated capabilities across development, manufacturing, quality, and regulatory support to deliver a comprehensive solution.

Financial Outlook and Timelines

This long-term agreement is expected to provide substantial business visibility, with revenue generation anticipated to commence from calendar year 2029.

• The current agreement covers 55 Stock Keeping Units (SKUs).
• Manufacturing will occur across three sites, with potential for adding more products.
• Annualized revenue potential is projected at approximately $90-100 million once all products are commercialized.
• Technology transfer activities are planned for completion within two years.

Market Performance Snapshot

Today’s trading saw Gland Pharma open at Rs. 2639.60, reaching an intraday high of Rs. 2,675.15 and a low of Rs. 2,632.50.

• The stock closed at Rs. 2600.45 previously, rising by 64.55 points.
• A total of 252 shares were traded on the counter.
• The 52-week high stands at Rs. 2,675.15 (10-Aug-2026), with a 52-week low of Rs. 1575.00 (16-Mar-2026).
• The company’s current market capitalization is Rs. 42898.76 crore.
• Promoters hold 51.77%, Institutions 39.18%, and Non-Institutions 9.05%.

Gland Pharma specializes in developing, manufacturing, and marketing complex injectables, primarily operating under a business-to-business model across numerous countries.